Endocrinology CME Courses

Endocrinology CME Courses

Credits: 1 (AMA PRA Category 1)
Format: Interactive Online
Price: Free
Release Date: 2/1/17
Expiration Date: 10/15/17
Summary:

Speakers:

  • Richard Beaser, MD. Associate Professor of Medicine, Harvard Medical School
  • Alissa R. Segal, PharmD, RPh, CDE, CDTC, FCCP. Associate Professor of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences
  • Jason Gaglia, MD, MMSc. Assitant Professor of Medicine, Harvard Medical School


Credits: 1 (AMA PRA Category 1)
Format: Interactive Online
Price: Free
Expiration Date: 6/14/18
Summary:

Speakers:

Matthew H. Kulke, MD, MMSc, Associate Professor of Medicine, Director of the Neuroendocrine and Carcinoid Tumor Program at Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School

David C. Metz, MBBCh, is Professor of Medicine at the Perelman School of Medicine (University of Pennsylvania)

Topic and Learning Objectives

  • To incorporate evidence-based practices into the management of carcinoid syndrome
  • Review the efficacy and safety of treatment programs for carcinoid syndrome
  • To summarize the causes of carcinoid syndrome
  • Review the differential diagnosis and appropriate workup for the presenting symptoms

This activity is intended for US-based medical oncologists, endocrinologists and gastroenterologists, as well as oncology physician assistants, nurse practitioners, and nurses involved in the diagnosis and management of carcinoid tumors and carcinoid syndrome. Considering the symptoms and potential complications involved in carcinoid syndrome, clinicians in cardiology, dermatology, pulmonary medicine, surgery, radiology (including interventional, diagnostic, and nuclear medicine), internal medicine and primary care may also benefit from education.

Credits: 0.75 (CE)
Format: Online Streaming Video, Interactive Online, Multiple Formats
Price: Free
Release Date: Nov 17, 2017
Expiration Date: Nov 17, 2019
Summary:

By the end of the session the participant will be able to:

  • Apply screening criteria to a patient receiving AI therapy or androgen deprivation therapy
  • Describe the criteria for initiation of pharmacotherapy in a patient receiving AI therapy or androgen deprivation therapy and apply them to a patient case
  • Identify present pharmacotherapeutic treatments for management of a patient receiving AI therapy or androgen deprivation therapy, and describe their mechanisms of action and place in therapy
  • Describe the challenges associated with treating patients receiving AI or androgen deprivation therapies, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents and apply the information in optimizing patient care in a patient case




Credits: 1 (CPE)
Format: Interactive Online, Online Download, Multiple Formats
Price: Free
Release Date: Feb 14, 2018
Expiration Date: Feb 14, 2020
Summary:

By the end of the session the participant will be able to:

  • Describe the underlying pathophysiological and typical clinical features of pediatric GHD as they pertain to therapeutic targets
  • Describe the optimal approach in diagnosing pediatric GHD and apply it to a patient case
  • Given a patient with pediatric GHD, design a pharmacotherapeutic regimen based on his or her clinical presentation
  • Evaluate patient cases during follow-up visits, including during transition therapy to adulthood when relevant, in a manner that optimizes one or more of the following: efficacy, safety, quality of life, or patient education and adherence
  • Describe best practices in tracking response to pediatric GHD therapy
Credits: 4 (AMA PRA Category 1)
Format: Online Streaming Video
Price: Free
Release Date: 9/14/2017
Expiration Date: 5/3/2018
Summary:

A four-part lecture series covering topics in insulin replacement for patients with type 2 diabetes mellitus (T2DM).

Share This